Steady as she goes.., page-39

This is from etrade news story today.


Resmed (RMD)

Resmed (RMD) is a world leader in the development, manufacturing and marketing of medical products to treat sleep apnoea.

Reasons to buy Resmed

While recent results from the SERVE-HF clinical trial are disappointing, we believe it is ring-fenced from the broader business as the device used in the trial represents <2% of total devices sold and the trial was not targeting the core patient segment; we estimate the total earnings impact at <3%.
The core respiratory and sleep-disorder breathing market remains intact, underpinned by a large and growing customer base, with favourable trends in obesity, ageing, cardiovascular diseases and increasing diagnosis rates; RMD controls c40% of this market.
It remains early days in a new platform cycle, with the rollout of new products the most concentrated vs the last four major product platform launches over 15 years. The quarterly result exceeded market expectations with double digit sales growth (+14%)
We retain our Add recommendation for RMD with a revised share price target of A$9.73ps (previously A$9.90).

By MORGANS